Pokaż cały numer - Farmaceutyczny Przegląd Naukowy

Farm Przegl Nauk, 2009,2
Tabela 5.
Macierz obserwowanych i przewidywanych klasyfikacji przypadków w grupach z zastosowaniem modelu
60
Macierz klasyfikacji Wiersze: obserwowana klasyfikacja Kolumny: Przewidywana klasyfikacja
Procent poprawnie G_1 G_2 G_3
G_1 100,0000 10 0 0
G_2 100,0000 0 20 0
G_3 100,0000 0 0 22
Razem 100,0000 10 20 22
Adres do korespondencji:
Elżbieta Brzezińska
Zakład Chemii Analitycznej UM w Łodzi,
ul. Muszyńskiego 1, 90-151 Łódź, tel. 042-677-92-11;
ebrzezinska@pharm.am.lodz.pl
Piśmiennictwo
1. Sternbach, L.H. The Benzodiazepines Story. J Med Chem
1979; 22: 1-7.
2. Johnson RE. i wsp.: 4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines:
a novel class III
antiarrhythmic agents. J Med Chem 1993; 36:3361-70.
3. Butcher JW. i wsp.: Novel 5-cyclopropyl-1,4-benzodiazepin-2ones
as potent and selective I(Ks)-blocking class III antiarrhythmic
agents. Bioorg Med Chem Lett 2003; 13(6): 1165-68.
4. Seebohm G. i wsp.: Molecular Determinants of KCNQ1
Channel Block by a Benzodiazepine. Mol Pharmacol 2003;
64: 70–77.
5. Shvetsa N. i wsp.: Study of the electronic and structural
features characteristic of 4,5-dihydro-1-phenyl-1H-2,4-
6.
benzodiazepines demonstrating antiarrhythmic activity. J
Mol Structure (Theochem) 1993; 463: 105–110.
Gupta S.P. Quantitative Structure-Activity Relationship Studies
on Cholecystokinin Antagonists. Current Pharm Design,
2002; 8: 111-124
7. Ursini A. i wsp.: Synthesis and SAR of new 5-phenyl-3ureido-1,5-benzodiazepines
as cholecystokinin-B receptor
antagonists. J Med Chem 2000; 43: 3596-3613
8. Evans B.E. i wsp.: Design of potent, orally effective non
peptidal antagonists of the peptide hormone cholecystokinin.
Proc Natl Acad Sci USA 1986; 83: 4918-22.
9. Kukla MJ. i wsp.: Synthesis and anti-HIV-1 activity of 4,5,6,7tetrahydro-5-methyloimidazo[4,5,1-jk][1,4]benzodiazepin-2-
(1H)-one (TIBO) derivatives. J Med Chem 1991; 34: 746-751.
10. Ren J. i wsp.: The structure of HIV-1 reverse transcriptase
complexed with 9-chloro-TIBO: lessons for inhibitor design.
Structure 1995; 3: 915-26.
11. Zhou Z., Madura JD. CoMFA 3D-QSAR Analysis of HIV-1
RT Nonnucleoside Inhibitors, TIBO Derivatives Based on
Docking Conformation and Alignment Chem. Inf Comput Sci
2004; 44: 2167 -2178.
12. Viroj W. Analysis of binding energy activity of TIBO and HIV
-RT based on simple consideration for conformational change
African J Biotech 2007; 6: 188-189.
13. Gower AJ. i wsp.: Pharmacological evaluation of in vivo tests
for alpha 2-adrenoceptor blockade in the central nervous system
and the effects of the enantiomers of mianserin and its aza-analog
ORG 3770 Arch Int Pharmacodyn Ther 1988; 291: 185-201.
14. Liebman JM. i wsp.: CGS 7525A, a new, centrally active alpha
2-adrenoceptor antagonist. Life Sci 1983; 32: 355-63.
15. Cappelli A. i wsp.: Synthesis, biological evaluation, and quantitative
receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines
as novel tifluadom-like ligands with
high affinity and selectivity for k-opioid receptors. J Med
Chem 1996; 39: 860–872.
16. Anzini M. i wsp.: Synthesis, Biological Evaluation, and Receptor
Docking Simulations of 2-[(Acylamino)ethyl]-1,4benzodiazepines
as k-Opioid Receptor Agonists Endowed
with Antinociceptive and Antiamnesic Activity. J Med Chem
2003; 46: 3853-3864.
17. Burkard WP. [H3] Tifluadom binding in guinea-pig brain
membranes. Eur J Pharmacol, 1984; 97: 337–338.
18. Romer D. i wsp.: Unexpected opioid activity in a known class
of drug. Life Sciences 1982; 31: 1217-20
19. Dor A., Krasnowska M. Wpływ pirenzepiny – wybiórczego
antagonisty receptorów M1, podanej po inhalacji ipratropium,
na wentylację płuc u chorych na przewleklą obturacujną chorobę
płuc Alergia Astma Immunologia 2000; 5: 193-196.
20. Baile CA. i wsp.: Endotoxin-elicited fever and anorexia and
elfazepam-stimulated feeding in sheep. Physiology and Behaviour
1981; 27: 271-277.
21. Van Den Broek GW. i wsp.: Feeding and depression of abomasal
secretion in sheep elicited by elfazepam and 9-azacannabinol
Pharmacol Biochem Behav 1979; 11: 51-6
22. Squires, RF., Saederup E. Clozapine and several other antipsychotic/antidepressant
drugs preferentially block the same
core fraction of GABAA receptors. Neurochem Res 1998; 23:
1283-1290.
23. Chebib M., Graham A., Johnston A. GABA-Activated Ligand
Gated Ion Channels: Medicinal Chemistry and Molecular
Biology. J Med Chem 2000; 43: 8.
24. Brea J. i wsp.: QF2004B, a potential antipsychotic butyrophenone
derivative with similar pharmacological properties to
clozapine Neuropharmacol 2006; 34: 1-12.
25. Kesäniemi YA., Miettinen TA. Inhibition of cholesterol absorption
by neomycin, benzodiazepine derivatives and ketoconazole
Eur J Clin Pharmacol 1991; 40 Suppl1: 65-7.
26. Breslin HJ. i wsp.: Synthesis and Anti-HIV-1 Activity of
4,5,6,7-Tetrahydro-5-methyloimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one
(TIBO) Derivatives. J Med Chem 1995;
38: 771-793.
27. Ho W. i wsp.: Synthesis and Anti-HIV-1 Activity of 4,5,6,7-
Tetrahydro-5-methyloimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one
(TIBO) Derivatives. J Med Chem 1995; 38:
794-802.
28. Breslin HJ. i wsp.: Synthesis and anti-HIV activity of 1,3,4,5tetrahydro-2H-1,4-benzodiazepin-2-one
(TBO) derivatives.
Truncated 4,5,6,7-tetrahydro-5-methyloimidazo[4,5,1-jk]
[1,4]benzodiazepin-2(1H)-one (TIBO) analogues. Bioorg
Med Chem 1999; 7: 2427-2436.
29. Brzezińska E. The QSAR analysis of tricyclic non-nucleoside
inhibitors of HIV-1 reverse transcriptase. Acta Polon Pharm
2003; 60: 3-13.
30. Brzezińska E., Glinka R. Serach for New non-nucleoside inhibitors
of HIV-1 reverse transcriptase (HIV-1 RT). Acta Polon
Pharm 2002; 59: 379-392.
31. Adams D. i wsp.: Preparation and Anti-HIV Activity of N-3
-Substituted Thymidine Nucleoside Analogs. J Med Chem
1997; 40: 1550-1558.
32. Schafer W. i wsp.: Non-nucleoside inhibitors of HIV-1 reverse
transcriptase: Molecular modeling and X-ray structure investigations.
J Med Chem 1993; 36: 726-733.